DBV Technologies publishes its financial results for the first quarter of 2024 and provides an update on its activities

DBV Technologies reported its financial results for the first quarter of 2024, marking several significant advancements for the biopharmaceutical company. In addition to the good progress of the phase 3 clinical study called VITESSE for the Viaskin Peanut patch, the appointment of Robert Pietrusko as Director of Regulatory Affairs strengthens the company's expertise.

The amount of cash available as of March 31, 2024 amounts to $101.5 million. However, there is doubt about the company's ability to continue trading beyond the next 12 months without additional financing.

The company's operating expenses increased from $23.4 million in the first quarter of 2023 to $30 million for the same period in 2024, primarily due to increased research and development spending. The net loss increased to $27.3 million from $20.6 million the previous year.